 This statement is inaccurate. The impact of acquired products and price increases was included in the companys 2015 guidance and subsequent guidance updates throughout the year include the $0.80 and $0.60 raises Valeant announced during our Q1 and Q2 earnings calls.

 The calculation is inaccurate, the real impact is significantly less once actual gross to net rates, timing of price increases, declining product volumes, and royalties to 3 rd parties are accounted for.

 The majority of products listed in the chart have generic alternatives available.

 For example: since January 2015 Valeant has raised the gross price of Solodyn 10% but realized a 0.7% net price increase.

 For example: since January 2015 Valeant has raised the gross price of Jublia 20% but realized 2% net price increase.

 All prices presented are WAC (gross) pricing and not the ASP (net) pricing Valeant actually achieves, which is significantly lower. The actual net effect is determined after taking into account any rebates/fees to: patients, managed care, government, wholesaler, group purchasing organizations, and customers.

 As stated in the point above the actual price increases achieved are much less than the gross increases taken.

 As stated in the first response above acquisitions at the time of guidance and price increases were included in our initial and subsequent guidance

 This is statement is inaccurate as Valeant did not make a stock offer to Salix

 Valeant discloses divestitures and discontinuations every quarter with our organic calculations in the press tables. Most recently for Q2 discontinuations was $10M on $2.7B of revenue, therefore the impact to organic growth would be not be significant at 0.37%.

AZ Blog

let me say right away as categorically as I possibly can that the $99M [in Sanitas cash generated] claimed by Valeant is a lie